These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 2149501)
21. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. Santen RJ; Worgul TJ; Samojlik E; Interrante A; Boucher AE; Lipton A; Harvey HA; White DS; Smart E; Cox C; Wells SA N Engl J Med; 1981 Sep; 305(10):545-51. PubMed ID: 7019703 [TBL] [Abstract][Full Text] [Related]
22. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. Geisler J; Lien EA; Ekse D; Lønning PE J Steroid Biochem Mol Biol; 1997; 63(1-3):53-8. PubMed ID: 9449206 [TBL] [Abstract][Full Text] [Related]
23. The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. Dowsett M; Shearer RJ; Ponder BA; Malone P; Jeffcoate SL Br J Cancer; 1988 Feb; 57(2):190-2. PubMed ID: 3358910 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. Coombes RC; Chilvers C; Dowsett M; Gazet JC; Ford HT; Bettelheim R; Gordon C; Smith IE; Zava D; Powles TJ Cancer Res; 1982 Aug; 42(8 Suppl):3415s-3419s. PubMed ID: 6211228 [TBL] [Abstract][Full Text] [Related]
25. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681 [TBL] [Abstract][Full Text] [Related]
26. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. Samojlik E; Veldhuis JD; Wells SA; Santen RJ J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women. Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561 [TBL] [Abstract][Full Text] [Related]
28. Aminoglutethimide in the treatment of advanced breast cancer. Stuart-Harris RC; Smith IE Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038 [No Abstract] [Full Text] [Related]
29. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950 [TBL] [Abstract][Full Text] [Related]
30. First generation aromatase inhibitors--aminoglutethimide and testololactone. Cocconi G Breast Cancer Res Treat; 1994; 30(1):57-80. PubMed ID: 7949205 [TBL] [Abstract][Full Text] [Related]
31. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346 [TBL] [Abstract][Full Text] [Related]
32. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast. Samojlik E; Santen RJ; Kirschner MA; Ertel NH Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199 [TBL] [Abstract][Full Text] [Related]
33. Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. Stuart-Harris R; Bradbrook I; Morrison P; Smith IE; Rogers HJ Br J Cancer; 1985 Apr; 51(4):485-92. PubMed ID: 3978028 [TBL] [Abstract][Full Text] [Related]
34. Role of aminoglutethimide in male breast cancer. Harris AL; Dowsett M; Stuart-Harris R; Smith IE Br J Cancer; 1986 Oct; 54(4):657-60. PubMed ID: 3778807 [TBL] [Abstract][Full Text] [Related]
35. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Plowman PN; Perry LA; Chard T Br J Urol; 1987 Mar; 59(3):255-7. PubMed ID: 3567487 [TBL] [Abstract][Full Text] [Related]
36. Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels. Carlström K; Pousette A; Rannevik G; Sköldefors H; Theve NO; Wilking N Breast Cancer Res Treat; 1986; 7 Suppl():S107-9. PubMed ID: 2943337 [No Abstract] [Full Text] [Related]
37. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885 [TBL] [Abstract][Full Text] [Related]
38. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer. Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857 [TBL] [Abstract][Full Text] [Related]
39. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma. Samojlik E; Santen RJ J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517 [TBL] [Abstract][Full Text] [Related]
40. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. Samojlik E; Santen RJ; Wells SA J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]